PATENT CLAIM ANALYSIS

Application Number: 15743092
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-03
Patent Classification: ["435", "006130"]

Abstract:
A pharmaceutical composition containing a lung cancer therapeutic agent and an SIRT inhibitor may minimize the expression of the resistance of lung cancer cells against the lung cancer therapeutic agent, thereby exerting an excellent lung cancer therapeutic effect. The treatment of lung cancer cells with a lung cancer therapeutic agent and the measurement of a level of SIRT1 expression may provide information for determining whether lung cancer cells have developed chemoresistance to a lung cancer therapeutic agent, and may screen lung cancer therapeutic agents.

Claim (Index 8):
A method for screening lung cancer therapeutic agents, the method comprising:\n treating lung cancer cells with a plurality of lung cancer therapeutic agents and then measuring a level of SIRT1 expression for each of the plurality of lung cancer therapeutic agents; and comparing the measured levels of SIRT1 expression.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 86.0
- Lexical Diversity: 2.0
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12026554', '12901139', '13058113', '14498618', '10508932']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5550410693759491
- 35 USC 102 Novelty (BERT): 0.5068469890012037
- Combined Prediction Score: 0.5502216613384746
- Mean Citation Score: 252.042706
- Max Citation Score: 261.61456
- Similarity Product: 168.66845567757602

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test